Callan JMB Announces First Quarter 2025 Financial Results and Provides Business Update
Callan JMB (NASDAQ: CJMB), a healthcare and emergency management logistics company, reported its Q1 2025 financial results following its February IPO. The company raised $5.7 million through its IPO at $4.00 per share. Q1 2025 financial results showed revenue of $1.45 million, with a gross profit margin of 42.5%, but reported a net loss of $1.2 million due to increased SG&A expenses and declining emergency preparedness service demand.
Key developments include appointing Christopher Shields as SVP of Emergency Preparedness & Response, renewing contracts with Texas DSHS, securing a five-year contract with Oregon Health Authority, and launching a vaccine management lease program. The company is expanding into GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services.
Callan JMB (NASDAQ: CJMB), un'azienda specializzata in logistica per la sanità e la gestione delle emergenze, ha comunicato i risultati finanziari del primo trimestre 2025 dopo la sua IPO di febbraio. La società ha raccolto 5,7 milioni di dollari tramite l'IPO, con un prezzo di 4,00 dollari per azione. I risultati del primo trimestre 2025 mostrano un fatturato di 1,45 milioni di dollari e un margine lordo del 42,5%, ma hanno registrato una perdita netta di 1,2 milioni di dollari a causa dell'aumento delle spese SG&A e della diminuzione della domanda per i servizi di preparazione alle emergenze.
Tra gli sviluppi principali si segnalano la nomina di Christopher Shields come SVP di Preparazione e Risposta alle Emergenze, il rinnovo dei contratti con il Texas DSHS, la firma di un contratto quinquennale con l'Oregon Health Authority e il lancio di un programma di leasing per la gestione dei vaccini. L'azienda sta inoltre ampliando le sue attività nel trasporto farmaceutico GLP-1, nella logistica per farmacie di preparazione specializzata e nei servizi di confezionamento alimentare premium.
Callan JMB (NASDAQ: CJMB), una empresa de logística en salud y gestión de emergencias, reportó sus resultados financieros del primer trimestre de 2025 tras su IPO en febrero. La compañía recaudó 5.7 millones de dólares a través de la IPO a 4.00 dólares por acción. Los resultados del primer trimestre mostraron ingresos de 1.45 millones de dólares con un margen bruto del 42.5%, pero reportaron una pérdida neta de 1.2 millones de dólares debido al aumento en gastos SG&A y a la disminución en la demanda de servicios de preparación para emergencias.
Entre los desarrollos clave se encuentran el nombramiento de Christopher Shields como SVP de Preparación y Respuesta a Emergencias, la renovación de contratos con Texas DSHS, la obtención de un contrato por cinco años con Oregon Health Authority y el lanzamiento de un programa de arrendamiento para gestión de vacunas. La empresa está expandiéndose en transporte farmacéutico GLP-1, logística para farmacias de compuestos especializados y servicios de empaques premium para alimentos.
Callan JMB (NASDAQ: CJMB)는 보건 및 비상 관리 물류 회사로, 2월 IPO 이후 2025년 1분기 재무 실적을 발표했습니다. 회사는 IPO를 통해 주당 4.00달러에 570만 달러를 조달했습니다. 2025년 1분기 재무 실적은 매출 145만 달러와 42.5%의 총이익률을 기록했으나, SG&A 비용 증가와 비상 대비 서비스 수요 감소로 인해 120만 달러의 순손실을 보고했습니다.
주요 발전 사항으로는 Christopher Shields의 비상 대비 및 대응 부문 수석 부사장(SVP) 임명, 텍사스 DSHS와의 계약 갱신, 오리건 보건 당국과의 5년 계약 체결, 백신 관리 리스 프로그램 출시가 있습니다. 또한 회사는 GLP-1 제약 운송, 전문 조제 약국 물류, 고급 식품 포장 서비스로 사업을 확장하고 있습니다.
Callan JMB (NASDAQ : CJMB), une entreprise spécialisée dans la logistique de la santé et la gestion des urgences, a publié ses résultats financiers du premier trimestre 2025 suite à son introduction en bourse en février. La société a levé 5,7 millions de dollars lors de cette IPO, à 4,00 dollars par action. Les résultats du premier trimestre 2025 montrent un chiffre d'affaires de 1,45 million de dollars avec une marge brute de 42,5%, mais affichent une perte nette de 1,2 million de dollars en raison de l'augmentation des frais SG&A et de la baisse de la demande pour les services de préparation aux urgences.
Parmi les faits marquants, on note la nomination de Christopher Shields en tant que SVP de la Préparation et Réponse aux Urgences, le renouvellement des contrats avec le Texas DSHS, la signature d'un contrat de cinq ans avec l'Oregon Health Authority, ainsi que le lancement d'un programme de location pour la gestion des vaccins. L'entreprise étend également ses activités au transport pharmaceutique GLP-1, à la logistique des pharmacies spécialisées en préparation et aux services d'emballage alimentaire haut de gamme.
Callan JMB (NASDAQ: CJMB), ein Unternehmen für Gesundheits- und Notfallmanagementlogistik, veröffentlichte seine Finanzergebnisse für das erste Quartal 2025 nach dem Börsengang im Februar. Das Unternehmen erzielte durch den Börsengang 5,7 Millionen US-Dollar bei 4,00 US-Dollar pro Aktie. Die Finanzergebnisse für Q1 2025 zeigten einen Umsatz von 1,45 Millionen US-Dollar mit einer Bruttomarge von 42,5%, meldeten jedoch aufgrund gestiegener SG&A-Kosten und rückläufiger Nachfrage nach Notfallvorsorgedienstleistungen einen Nettoverlust von 1,2 Millionen US-Dollar.
Wichtige Entwicklungen umfassen die Ernennung von Christopher Shields zum Senior Vice President für Notfallvorsorge und -reaktion, die Vertragsverlängerung mit Texas DSHS, den Abschluss eines fünfjährigen Vertrags mit der Oregon Health Authority sowie die Einführung eines Leasingprogramms für Impfstoffmanagement. Das Unternehmen erweitert zudem sein Geschäft auf den GLP-1-Pharma-Transport, spezialisierte Apothekenlogistik und Premium-Lebensmittelverpackungsdienste.
- Successfully completed IPO raising $5.7 million in gross proceeds
- Strong gross profit margin of 42.5%
- Secured new five-year contract with Oregon Health Authority
- Strategic expansion into high-growth markets (GLP-1 pharmaceuticals, specialized pharmacy logistics)
- Key executive hire with Christopher Shields appointment
- Posted net loss of $1.2 million in Q1 2025
- Revenue declined due to decreased demand for emergency preparedness services
- Increased SG&A expenses due to IPO-related costs and new executive payroll
- Recently public company with limited operating history as a public entity
Insights
Callan JMB's Q1 results show concerning revenue decline and operating losses following recent IPO, signaling challenging early public market performance.
Callan JMB's first quarterly report as a public company reveals some concerning financial metrics that investors should carefully evaluate. The company reported
The
The cash burn rate is concerning - if quarterly losses continue at
The timing of this IPO raises questions about market readiness, as the company went public at
Callan JMB faces revenue challenges but is strategically diversifying beyond emergency services into high-growth healthcare logistics markets.
Callan JMB is executing a classic pivot strategy in the specialized healthcare logistics sector. Their core emergency preparedness business, which drove initial growth during the pandemic, is clearly contracting as government agencies reduce spending in this area. The company explicitly acknowledges this as the cause of their revenue decline, which is an honest but concerning admission for investors.
The strategic positioning appears sound despite financial challenges. The company is targeting high-growth segments within healthcare logistics where specialized capabilities create competitive advantages. The GLP-1 market represents a particularly promising opportunity, as these weight loss/diabetes medications require sophisticated cold chain management and are experiencing exponential demand growth. Similarly, compounding pharmacies require precise logistics given regulatory requirements and temperature sensitivity of customized medications.
The company's infrastructure investments are being leveraged appropriately through new service models like the vaccine management lease program. This approach lowers barriers to entry for customers while creating recurring revenue opportunities for Callan JMB, potentially stabilizing future income streams.
The renewed contracts with Texas DSHS and the new five-year Oregon Health Authority agreement demonstrate the company retains government client trust despite spending reductions. The standby arrangement for measles outbreak response shows their services remain valued for emergency situations. However, the transition to "sustainment phase" language confirms that pandemic-era emergency spending levels aren't returning.
For stability, Callan JMB must accelerate diversification into commercial healthcare logistics while maintaining government relationships. Their public listing provides working capital for this transition, but execution speed is critical given their current burn rate and revenue challenges.
Completed Initial Public Offering (IPO) on February 6, 2025, at
SPRING BRANCH, Texas, May 15, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced its financial results for the first quarter ended March 31, 2025 and is providing a business update.
"Callan JMB is establishing itself as the premier provider of advanced logistics and value-added fulfillment services across high-growth sectors," stated Wayne Williams, CEO & Chairman of Callan JMB. "By leveraging our core competitive strengths, we are strategically scaling our proven business model into emerging markets where our expertise creates significant value. Our innovative solutions are disrupting traditional approaches by delivering customized configurations that precisely meet our client’s needs. We are actively pursuing growth opportunities in rapidly expanding markets, including GLP-1 pharmaceutical transportation, specialized compounding pharmacy logistics, and premium food packaging services. We are already engaged in promising discussions with potential partners in these sectors and look forward to sharing developments in the near future."
"Simultaneously, we are executing a national expansion of our emergency preparedness and response operations. We have identified substantial growth potential in untapped metropolitan areas and states, and our recent appointment of Christopher Shields as Senior Vice President of Emergency Preparedness & Response/Government Affairs will accelerate our geographic expansion. Callan JMB is well positioned for sustained growth and market leadership as we progress through 2025," concluded Mr. Williams.
Business Highlights to Date:
- On February 6, 2025, completed IPO at
$4.00 per share with gross proceeds of approximately$5.7 million , including partial exercise of over-allotment. - Announced the appointment of former Assistant Commissioner of the Chicago Department of Public Health, Christopher Shields, as Senior Vice President, Emergency Preparedness & Response/Government Affairs.
- Requested by the State of Texas Department of Health and Human Services to be on standby in readiness to assist with the response to the recent outbreak of measles.
- Renewed the Company’s arrangement with the Texas Department of State Health Services (DSHS) as the state transitions from heightened readiness to a sustainment phase following the COVID-19 pandemic. Callan JMB will provide ongoing updates on facility and personnel readiness while consulting with the DSHS to maintain alignment for potential future elevated status responses as part of its contract with the agency.
- Granted a second five-year contract by the Oregon Health Authority for medical emergency preparedness and response services. The new contract includes Callan JMB’s services for storing and managing a broad inventory of medical countermeasures to meet all new threat assessments and event response missions in the State of Oregon.
- Commenced a comprehensive lease program for vaccine management, enabling government agencies and private organizations to provide crucial immunizations without the financial burden of purchasing equipment outright.
- Supported Health Hero Tennessee with its voluntary, statewide immunization initiative.
Financial Highlights for the Year Ended March 31, 2025:
- Revenue for the first quarter of 2025 of
$1.45 million . The decrease in revenue this quarter was due to the decline in demand for our emergency preparedness services by certain states and local governments. - Cost of revenue for the first quarter of 2025 of
$0.8 million . - Gross profit and gross profit margin for the first quarter of 2025 totaled
$0.6 million and42.5% , respectively. - SG&A expenses for the first quarter of 2025 were
$1.9 million . The increase year-over-year was primarily driven by an increase in consulting and professional fees related to the Company’s IPO and adding the Company’s CEO to payroll for the first time, along with other senior staff hires to support future growth. - Operating income (loss) for the first quarter of 2025 was (
$1.2) million . - Net income (loss) for the first quarter of 2025 was (
$1.2) million .
About Callan JMB Inc.
Callan JMB Inc. is an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services to secure medical materials and protect patients and communities with compliant, safe, and effective medicines. Our combined expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance and emergency preparedness is unparalleled in the industry. We offer a gold standard in client experience with customizable interfaces, next-level reliability in shipping and environmental sustainability in our specialty packaging.
Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.
Investor Contacts:
Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254
CALLAN JMB INC.
(Formerly known as Coldchain Technology Services, LLC)
CONDENSED CONSOLIDATED BALANCE SHEETS as of
March 31, 2025 (Unaudited) AND DECEMBER 31, 2024
| March 31, 2025 | December 31, 2024 | |||||||
| Assets | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 5,219,929 | $ | 2,097,945 | ||||
| Accounts receivable, net of allowance for credit losses of | 834,956 | 622,914 | ||||||
| Inventory | 216,046 | 158,362 | ||||||
| Related party loans | - | 18,669 | ||||||
| Tax refund receivable | - | 6,377 | ||||||
| Prepaid insurance | 350,845 | 151,354 | ||||||
| Other current assets | 180,328 | 127,542 | ||||||
| Deferred offering costs | - | 136,025 | ||||||
| Total current assets | 6,802,104 | 3,319,188 | ||||||
| Right of use asset | 799,739 | 883,029 | ||||||
| Property and equipment, net | 853,823 | 876,682 | ||||||
| Security deposit | - | 3,650 | ||||||
| Total assets | $ | 8,455,666 | $ | 5,082,549 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 389,941 | $ | 371,661 | ||||
| Accrued expenses – Note 5 | 390,461 | 506,381 | ||||||
| Corporate taxes payable | 27,106 | 23,000 | ||||||
| Deferred revenue | 5,045 | 94,097 | ||||||
| Right of use liability – current | 236,343 | 279,176 | ||||||
| Total current liabilities | 1,048,896 | 1,274,315 | ||||||
| Right of use liability | 592,587 | 628,274 | ||||||
| Deferred tax liability | 6,602 | 6,602 | ||||||
| Total long-term liabilities | 599,189 | 634,876 | ||||||
| Total liabilities | 1,648,085 | 1,909,191 | ||||||
| Commitments and Contingencies – Note 10 | ||||||||
| Stockholders’ Equity | ||||||||
| Preferred stock - authorized 10,000,000 shares, | - | - | ||||||
| Common stock - authorized 190,000,000 shares, par value | 4,444 | 3,000 | ||||||
| Additional Paid in Capital | 10,337,375 | 5,464,006 | ||||||
| Accumulated Deficit | (3,534,238 | ) | (2,293,648 | ) | ||||
| Total Stockholders’ Equity | 6,807,581 | 3,173,358 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 8,455,666 | $ | 5,082,549 | ||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 and 2024 (Unaudited)
| Three months ended March 31, 2025 | Three months ended March 31, 2024 | |||||||
| Revenue | $ | 1,449,377 | $ | 1,790,521 | ||||
| Cost of revenue | 833,437 | 1,072,938 | ||||||
| Gross profit | 615,940 | 717,583 | ||||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | 1,854,316 | 805,042 | ||||||
| Operating loss | (1,238,376 | ) | (87,459 | ) | ||||
| Other income (expenses) | ||||||||
| Interest income | 2,209 | 3,433 | ||||||
| Interest expense | (63 | ) | (3,107 | ) | ||||
| Total other income (expenses) | 2,146 | 326 | ||||||
| Loss before income taxes | (1,236,230 | ) | (87,133 | ) | ||||
| Provision (benefit) for income taxes | 4,360 | (6,000 | ) | |||||
| Net loss | $ | (1,240,590 | ) | $ | (81,133 | ) | ||
| Weighted average common shares outstanding - basic and diluted | 3,862,507 | 2,500,000 | ||||||
| Net loss per common share - basic and diluted | $ | (0.32 | ) | $ | (0.03 | ) | ||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
(Unaudited)
| For the three months ended March 31, 2025 | For the three months ended March 31, 2024 | |||||||
| Cash flows from operating activities | ||||||||
| Net loss | $ | (1,240,590 | ) | $ | (81,133 | ) | ||
| Adjustment to reconcile net loss to net cash provided by (used in) operating activities: | ||||||||
| Depreciation and amortization | 37,857 | 35,578 | ||||||
| Provision (Recovery) for credit losses | (17,120 | ) | - | |||||
| Stock based compensation | 330,825 | - | ||||||
| Changes in operating assets and liabilities | ||||||||
| Accounts receivable | (194,922 | ) | (182,173 | ) | ||||
| Inventory | (57,684 | ) | (7,908 | ) | ||||
| Tax refund receivable | 6,377 | - | ||||||
| Prepaid insurance | (199,491 | ) | ||||||
| Other current assets | (52,785 | ) | 22,258 | |||||
| Right of use asset - net | 4,770 | 224 | ||||||
| Security Deposits and other assets | 3,650 | - | ||||||
| Accounts payable and accrued expenses | (97,639 | ) | 229,022 | |||||
| Deferred revenue | (89,052 | ) | (3,029 | ) | ||||
| Corporate taxes payable | 4,106 | (6,000 | ) | |||||
| Net cash provided by (used in) operating activities | (1,561,698 | ) | 6,839 | |||||
| Cash flows used in investing activities | ||||||||
| Purchase of property and equipment | (15,000 | ) | (44,656 | ) | ||||
| Net cash used in investing activities | (15,000 | ) | (44,656 | ) | ||||
| Cash flows from (used in) financing activities | ||||||||
| Related party loans | 18,669 | (17,073 | ) | |||||
| Deferred offering costs | - | (25,000 | ) | |||||
| Partner distributions | - | (3,382,253 | ) | |||||
| Increase (decrease) in note payable | - | (35,960 | ) | |||||
| Proceeds from IPO and overallotment, net | 4,680,013 | - | ||||||
| Net cash used in financing activities | 4,698,682 | (3,460,286 | ) | |||||
| Increase (decrease) in cash | 3,121,984 | (3,498,103 | ) | |||||
| Cash beginning of period | 2,097,945 | 5,155,620 | ||||||
| Cash end of period | $ | 5,219,929 | $ | 1,657,517 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | 63 | $ | 3,107 | ||||
| Supplemental Schedule of Non-Cash Financing and Investing Activities: | ||||||||
| Membership exchange for common stock | $ | - | $ | 5,413,007 | ||||
| Fair value of Stock Warrants issued at IPO | $ | 144,358 | $ | - | ||||
| Deferred offering costs charged to additional paid-in-capital | $ | 136,025 | $ | - | ||||
FAQ
What were Callan JMB's (CJMB) Q1 2025 financial results?
How much did Callan JMB raise in its IPO and at what price?
What new markets is CJMB expanding into?
What major contracts did Callan JMB secure recently?
Who is Christopher Shields and what is his role at CJMB?
